Orphazyme
ISIN: DK0060910917 | Ticker: ORPHA | LEI: 54930025OZD2GGSQ7L42
Country: Denmark
Orphazyme was founded in Denmark in 2009 on a scientific discovery about the role of heat shock proteins (HSPs), which was described in a well-cited article published in the journal Nature.
We translated this scientific discovery into late-stage clinical trials of our investigational drug candidate, arimoclomol, with the aim of developing new treatment options for people with neurodegenerative diseases, such as Niemann-Pick disease type-C (NPC).
In May 2022, substantially all of Orphazyme’s assets and business activities, including those relating to the development and approval of arimoclomol, were sold to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm, Inc.
2009
HeadquartersOle Maaløes Vej 3, 2200 Copenhagen – Denmark
| Line item in (dkk) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.07.2021 | 01.01.2022 | 01.07.2022 | 01.01.2023 | 01.07.2023 |
|---|---|---|---|---|---|---|---|---|
| Assets | N/A | N/A | 822,493,000.00 | N/A | 173,229,000.00 | 93,589,000.00 | 58,122,000.00 | 36,181,000.00 |
| Noncurrent Assets | N/A | N/A | 38,829,000.00 | N/A | 14,285,000.00 | 5,500,000.00 | 0.00 | N/A |
| Property Plant And Equipment | N/A | N/A | 4,687,000.00 | N/A | 2,985,000.00 | 0.00 | 0.00 | N/A |
| Intangible Assets Other Than Goodwill | N/A | N/A | 12,454,000.00 | N/A | 2,152,000.00 | 0.00 | 0.00 | N/A |
| Deferred Tax Assets | N/A | N/A | 2,065,000.00 | N/A | 0.00 | 0.00 | N/A | N/A |
| Current Tax Assets Noncurrent | N/A | N/A | 2,750,000.00 | N/A | 2,750,000.00 | 5,500,000.00 | 0.00 | N/A |
| Current Assets | N/A | N/A | 783,664,000.00 | N/A | 158,944,000.00 | 88,089,000.00 | 58,122,000.00 | 36,181,000.00 |
| Inventories | N/A | N/A | 0.00 | N/A | 0.00 | N/A | 0.00 | N/A |
| Current Trade Receivables | N/A | N/A | 0.00 | N/A | 29,268,000.00 | 23,765,000.00 | 4,103,000.00 | 0.00 |
| Current Tax Assets Current | N/A | N/A | 5,500,000.00 | N/A | 7,229,000.00 | 7,388,000.00 | 7,338,000.00 | 5,500,000.00 |
| Cash and cash equivalents | N/A | N/A | 726,929,000.00 | 334,184,000.00 | 102,255,000.00 | 49,532,000.00 | 42,464,000.00 | 30,340,000.00 |
| Cash | 394,706,000.00 | 123,588,000.00 | 726,929,000.00 | N/A | 102,255,000.00 | 49,532,000.00 | 42,464,000.00 | 30,340,000.00 |
| Equity And Liabilities | N/A | N/A | 822,493,000.00 | N/A | 173,229,000.00 | 93,589,000.00 | 58,122,000.00 | 36,181,000.00 |
| Equity | 388,249,000.00 | 52,969,000.00 | 620,525,000.00 | 166,761,000.00 | 9,339,000.00 | 78,205,000.00 | 41,667,000.00 | 28,883,000.00 |
| Issued Capital | N/A | N/A | 34,698,000.00 | N/A | 34,952,000.00 | 35,312,000.00 | 35,312,000.00 | 35,312,000.00 |
| Retained Earnings | N/A | N/A | -1,502,921,000.00 | N/A | -2,110,998,000.00 | -2,046,990,000.00 | -2,080,588,000.00 | -2,093,372,000.00 |
| Share Premium | N/A | N/A | 2,082,254,000.00 | N/A | 2,082,486,000.00 | 2,087,436,000.00 | 2,087,436,000.00 | 2,087,436,000.00 |
| Other Reserves | N/A | N/A | 6,494,000.00 | N/A | 2,899,000.00 | 2,447,000.00 | -493,000.00 | -493,000.00 |
| Noncurrent Liabilities | N/A | N/A | 35,341,000.00 | N/A | 34,798,000.00 | 0.00 | 98,000.00 | N/A |
| Other Noncurrent Liabilities | N/A | N/A | 1,634,000.00 | N/A | 98,000.00 | 0.00 | 98,000.00 | N/A |
| Longterm Borrowings | N/A | N/A | 23,830,000.00 | N/A | 2,482,000.00 | 0.00 | 0.00 | N/A |
| Current Liabilities | N/A | N/A | 166,627,000.00 | N/A | 129,092,000.00 | 15,384,000.00 | 16,357,000.00 | 7,298,000.00 |
| Current Provisions | N/A | N/A | 0.00 | N/A | 0.00 | N/A | N/A | N/A |
| Current Tax Liabilities Current | N/A | N/A | 4,159,000.00 | N/A | 584,000.00 | 334,000.00 | 284,000.00 | 0.00 |
| Other Current Liabilities | N/A | N/A | 53,327,000.00 | N/A | 29,523,000.00 | 3,688,000.00 | 1,075,000.00 | 5,510,000.00 |
| Line item in (dkk) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.07.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.07.2022 |
01.01.2022/ 01.01.2023 |
01.01.2023/ 01.07.2023 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | N/A |
| Profit Loss From Operating Activities | -335,954,000.00 | -608,534,000.00 | -57,344,000.00 | -633,303,000.00 | -27,296,000.00 | N/A | -12,834,000.00 |
| Finance Income | 316,000.00 | 2,444,000.00 | 25,000.00 | 37,000.00 | 56,000.00 | 193,000.00 | 50,000.00 |
| Finance Costs | 7,359,000.00 | 29,071,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | N/A |
| Profit Loss Before Tax | -342,997,000.00 | -635,161,000.00 | -57,319,000.00 | -83,436,000.00 | -27,239,000.00 | -41,048,000.00 | -12,784,000.00 |
| Income Tax Expense Continuing Operations | -5,500,000.00 | -1,915,000.00 | -2,318,000.00 | -4,941,000.00 | -2,793,000.00 | -2,736,000.00 | 0.00 |
| Profit Loss From Continuing Operations | N/A | N/A | -55,002,000.00 | -78,495,000.00 | -24,446,000.00 | -38,312,000.00 | -12,784,000.00 |
| Profit Loss From Discontinued Operations | N/A | N/A | -408,778,000.00 | -548,044,000.00 | 87,429,000.00 | 64,382,000.00 | 0.00 |
| Profit (loss) | -337,497,000.00 | -633,246,000.00 | -463,780,000.00 | -626,539,000.00 | 62,983,000.00 | 26,070,000.00 | -12,784,000.00 |
| Line item in (dkk) | 01.01.2020 | 01.01.2021 | 01.07.2021 | 01.01.2022 | 01.07.2022 | 01.01.2023 | 01.07.2023 |
|---|---|---|---|---|---|---|---|
| Profit (loss) | -337,497,000.00 | -633,246,000.00 | -463,780,000.00 | -626,539,000.00 | 62,983,000.00 | 26,070,000.00 | -12,784,000.00 |
| Adjustments For Income Tax Expense | -5,500,000.00 | -1,915,000.00 | N/A | -4,941,000.00 | N/A | N/A | N/A |
| Adjustments For Finance Costs | 7,359,000.00 | 29,071,000.00 | N/A | 10,608,000.00 | N/A | N/A | N/A |
| Adjustments For Depreciation And Amortisation Expense | 3,803,000.00 | 5,200,000.00 | N/A | 18,111,000.00 | N/A | 1,820,000.00 | N/A |
| Adjustments For Unrealised Foreign Exchange Losses Gains | 0.00 | 0.00 | N/A | 0.00 | N/A | N/A | N/A |
| Adjustments For Sharebased Payments | 2,549,000.00 | 28,105,000.00 | N/A | 16,019,000.00 | N/A | 1,773,000.00 | N/A |
| Interest Paid Classified As Operating Activities | 5,181,000.00 | 10,723,000.00 | N/A | 6,263,000.00 | N/A | 1,132,000.00 | N/A |
| Interest Received Classified As Operating Activities | 388,000.00 | 45,000.00 | N/A | 37,000.00 | N/A | 193,000.00 | N/A |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | N/A | 4,181,000.00 | N/A | 0.00 | N/A | N/A |
| Cash Flows From Used In Operating Activities | -326,818,000.00 | -539,076,000.00 | 2,591,000.00 | -602,571,000.00 | -116,472,000.00 | -117,945,000.00 | -12,124,000.00 |
| Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | N/A | N/A | 0.00 | N/A | 88,887,000.00 | N/A |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | 0.00 | 0.00 | N/A | 1,040,000.00 | N/A | 1,460,000.00 | N/A |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 2,777,000.00 | 2,365,000.00 | 0.00 | 92,000.00 | 0.00 | 0.00 | N/A |
| Purchase Of Intangible Assets Classified As Investing Activities | 508,000.00 | 2,736,000.00 | 0.00 | 902,000.00 | 0.00 | 0.00 | N/A |
| Cash Flows From Used In Investing Activities | -3,285,000.00 | -5,101,000.00 | 0.00 | 46,000.00 | 0.00 | 90,347,000.00 | N/A |
| Proceeds From Issuing Shares | 19,000.00 | 1,280,786,000.00 | 464,000.00 | 464,000.00 | 5,310,000.00 | 5,451,000.00 | 0.00 |
| Proceeds From Borrowings Classified As Financing Activities | 62,758,000.00 | 0.00 | N/A | 0.00 | N/A | N/A | N/A |
| Repayments Of Borrowings Classified As Financing Activities | 0.00 | 10,535,000.00 | N/A | 25,657,000.00 | N/A | 39,155,000.00 | N/A |
| Payments Of Lease Liabilities Classified As Financing Activities | 3,838,000.00 | 2,970,000.00 | N/A | 3,503,000.00 | N/A | 1,233,000.00 | N/A |
| Cash Flows From Used In Financing Activities | 58,939,000.00 | 1,159,422,000.00 | -1,148,000.00 | -30,344,000.00 | 5,310,000.00 | -35,078,000.00 | 0.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | -271,164,000.00 | 615,245,000.00 | N/A | -632,869,000.00 | N/A | N/A | N/A |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | 46,000.00 | -11,904,000.00 | 5,311,000.00 | 8,195,000.00 | -5,138,000.00 | 2,885,000.00 | 0.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | N/A | -398,056,000.00 | -632,869,000.00 | -47,585,000.00 | -62,676,000.00 | -12,124,000.00 |
| Cash and cash equivalents | N/A | 726,929,000.00 | 334,184,000.00 | 102,255,000.00 | 49,532,000.00 | 42,464,000.00 | 30,340,000.00 |
Please note that some sums might not add up.
DK0060910917
LEI54930025OZD2GGSQ7L42
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.